AbstractIn this study, a novel La(III)‐based two‐dimensional (2D) metal‐organic framework, [La2/3(qptca)1/2] (referred to as SLX‐2), from LaCl3 and 1,1′ : 4′,1′′ : 4′′,1′′′ : 4′′′,1′′′′‐quinquephenyl]‐2,2′′,2′′′′,5′′‐tetracarboxylic acid (H4qptca) was synthesized by conventional solvothermal method and thoroughly characterized by using X‐ray single‐crystal diffraction, powder X‐ray diffraction, and thermogravimetric analyses. The 2D SLX‐2 features a unique lanthanum center exposed to the skeleton and was used as an efficient Lewis acid catalyst for the Friedel‐Crafts alkylation of indole and pyrrole with β‐nitrostyrene along with a wide substrate scope, giving the desired products in good‐to‐high yields under the optimal reaction conditions. Furthermore, the catalyst was used for twenty cycles, with nearly no effect on its activity, and the reaction was heterogeneous in nature. Moreover, compared to the previous hydrogen‐bond‐donating MOF catalysts for such alkylation reactions, SLX‐2 showed an excellent stability toward harsh acidic and basic environment, and gave comparable catalytic activities.

01 Dec 2022·Pharmacological Research

Efficacy of mucosal vaccination using a protozoan parasite as a vehicle for antigen delivery: IgG and neutralizing response after rectal administration of LeCoVax-2, a candidate vaccine against COVID-19

Article

Author: Fiorina, Paolo ; Cattaneo, Giulia Maria ; Gabrieli, Paolo ; Bertola, Luca ; Leonardi, Margherita ; Varotto-Boccazzi, Ilaria ; Recordati, Camilla ; Epis, Sara ; Montomoli, Emanuele ; Razzano, Ilaria ; Dapporto, Francesca ; Manenti, Alessandro ; Bandi, Claudio ; Iannacone, Matteo ; Gourlay, Louise ; Rubolini, Diego ; Monti, Martina ; Zuccotti, Gianvincenzo ; Marvasi, Luigi

Mucosal vaccination is regarded as a promising alternative to classical, intramuscular vaccine delivery. However, only a limited number of vaccines have been licensed for mucosal administration in humans. Here we propose Leishmania tarentolae, a protozoan parasite, as a potential antigen vehicle for mucosal vaccination, for administration via the rectal or oral routes. To test this hypothesis, we exploited L. tarentolae for the production and delivery of SARS-CoV-2 antigens. Two antigens were assayed in BALB/c mice: Lt-spike, a L. tarentolae clone engineered for the surface expression of the SARS-CoV-2 spike protein; RBD-SD1, a purified portion of the spike protein, produced by another engineered clone of the protozoon. Immune response parameters were then determined at different time points. Both antigens, administered either separately or in combination (Lt-spike + RBD-SD1, hereafter LeCoVax-2), determined significant IgG seroconversion and production of neutralizing antibodies after subcutaneous administration, but only in the presence of adjuvants. After rectal administration, the purified RBD-SD1 antigen did not induce any detectable immune response, in comparison with the intense response observed after administration of LeCoVax-2 or Lt-spike alone. In rectal administration, LeCoVax-2 was also effective when administered without adjuvant. Our results show that L. tarentolae is an efficient and safe scaffold for production and delivery of viral antigens, to be used as vaccines. In addition, rectal vaccination experiments prove that L. tarentolae is suitable as a vaccine vehicle and adjuvant for enteral vaccination. Finally, the combined preparation LeCoVax-2 can be considered as a promising candidate vaccine against SARS-CoV-2, worthy of further investigation.

01 Jan 2017·European Journal of CancerQ1 · MEDICINE

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer

Q1 · MEDICINE

Article

Author: Rustin, Gordon ; Fong, Peter C ; Lorusso, Domenica ; Hall, Marcia ; Mirza, Mansoor Raza ; Berger, Regina ; Monk, Bradley J ; Vergote, Ignace ; Wenham, Robert M ; Colombo, Nicoletta ; Oberaigner, Willi ; Vuylsteke, Peter ; Scambia, Giovanni ; Vogl, Florian D ; Kristeleit, Rebecca ; Altintas, Sevilay ; Marth, Christian ; Renard, Vincent ; Bach, Bruce A ; Clamp, Andrew ; Kurzeder, Christian ; Oza, Amit ; Pignata, Sandro ; Ma, Haijun

AIMSTrebananib, a peptide-Fc fusion protein, inhibits angiogenesis by inhibiting binding of angiopoietin-1/2 to the receptor tyrosine kinase Tie2. This randomised, double-blind, placebo-controlled phase 3 study evaluated whether trebananib plus pegylated liposomal doxorubicin (PLD) improved progression-free survival (PFS) in patients with recurrent epithelial ovarian cancer.METHODSWomen with recurrent ovarian cancer (platinum-free interval ≤12 months) were randomised to intravenous PLD 50 mg/m² once every 4 weeks plus weekly intravenous trebananib 15 mg/kg or placebo. PFS was the primary end-point; key secondary end-points were objective response rate (ORR) and duration of response (DOR). Owing to PLD shortages, enrolment was paused for 13 months; the study was subsequently truncated.RESULTSTwo hundred twenty-three patients were enrolled. Median PFS was 7.6 months (95% CI, 7.2-9.0) in the trebananib arm and 7.2 months (95% CI, 4.8-8.2) in the placebo arm, with a hazard ratio of 0.92 (95% CI, 0.68-1.24). However, because the proportional hazards assumption was not fulfilled, the standard Cox model did not provide a reliable estimate of the hazard ratio. ORR in the trebananib arm was 46% versus 21% in the placebo arm (odds ratio, 3.43; 95% CI, 1.78-6.64). Median DOR was improved (trebananib, 7.4 months [95% CI, 5.7-7.6]; placebo, 3.9 months [95% CI, 2.3-6.5]). Adverse events with a greater incidence in the trebananib arm included localised oedema (61% versus 32%), ascites (29% versus 9%) and vomiting (45% versus 33%).CONCLUSIONSTrebananib demonstrated anticancer activity in this phase 3 study, indicated by improved ORR and DOR. Median PFS was not improved. No new safety signals were identified.TRIAL REGISTRATIONClinicalTrials.gov, NCT01281254.

100 Deals associated with LeCoVax-2

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Coronavirus Infections	Preclinical	IT	University of Milan	03 Nov 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

LeCoVax-2

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation